In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic collagen-induced arthritis model a pre-clinical study
kinase inhibitors: optimization of a series of biphenylamides for clinical progression. to give a J Med Chemmolecule suitable 6. 52: 6257-69.
2009; MILLER collagen EJ: Structural studies on cartilage
solubilization employing with limited cleavage and 7. 1972, 11: 4903-9.
pepsin. Biochemistry WILLIAMS Anti-tumor necrosis factor ameliorates joint RO, FELDMANN M, MAINI RN:
disease in murine collagen-induced arthritis. 8. Proc Natl Acad Sci USA WILLIAMS MAINI anti-tumor RN: RO, Synergy MASON 1992, 89: 9784-8.between LJ, FELDMANN M,
tion tis. Proc Natl Acad Sci USA of established necrosis collagen-induced factor in anti-CD4 the ameliora-and 1994, 91: 2762-arthri- 9. 6.
WILLIAMS MAINI induced arthritis with TNF receptor-IgG fu-RN: RO, Successful GHRAYEB therapy J, FELDMANN of collagen-M,
sion protein and combination with anti-CD4. 10. Immunology MIOTLA FELDMANN J, 1995, 84: 433-9.
MACIEWICZ R, with soluble VEGF receptor reduces disease M, PALEOLOG KENDREW E: Treatment J,
severity in murine collagen-induced arthritis. 11. Lab Invest WILLIAMS 2000, 80: 1195-205.
L, of FELDMANN RO, MARINOVA-MUTAFCHIEVA
gen-induced TNF-alpha and M, IL-1 MAINI blockade RN: Evaluation in colla-combined anti-TNF-alpha/anti-CD4 therapy. arthritis and comparison with 12. J Immunol AFUWAPE 2000, 165: 7240-5.
Adenoviral A, ceptor delivery FELDMANN of soluble M, PALEOLOG E:
in 1 (sFlt-1) abrogates disease VEGF re-13. Therapy murine collagen-induced arthritis. activity Gene SUMARIWALLA P, CAO Y2003, 10: 1950-60.
M, PALEOLOG Eprotease-activated : The angiogenesis inhibitor , WU H, FELDMANN
severity of murine collagen-induced arthritis. kringles 1-5 reduces the 14. Arthritis Res Ther SUMARIWALLA Antagonism of the human epidermal growth PF, 2003, 5:R32-R39.
JIN P, ZHANG J et al.:
factor verity receptor in murine family collagen-induced controls disease arthritis. se-15. Arthritis Rheum HOLMDAHL 2008, 58: 3071-80.
RUBIN K, KLARESKOG LR, JANSSON L, LARSSON E,
II collagen induces chronic : Homologous type and progressive
arthritis 16. 29:106-13.
in mice. Arthritis Rheum 1986, GROSJEAN J, KIRIAKIDIS S, REILLY K, FELD-MANN thelial growth factor signalling in endothelial M, PALEOLOG E: Vascular endo-
cell survival: A role for NFkappaB. 17. Biophys Res Commun BADGER AM, BRADBEER JN, VOTTA B, LEE
2006, 340: 984-94.Biochem JC, logical ADAMS JL, GRISWOLD DE: inhibitor pro le of SB 203580, a Pharmaco-protein/p38 of thritis, bone resorption, endotoxin shock and kinase, cytokine in animal suppressive selective models binding of ar-immune function. J Pharmacol Exp 18. 1996, 279: 1453-61.
Ther BARONE SB togen-activated 239063, FC, a IRVING second-generation EA, RAY AMp38 et al.:
duces protein kinase inhibitor, mi-re-in cerebral focal ischemia. brain injury and neurological de cits 19. Ther J Pharmacol Exp Det E DIOS 2001, 296: 312-21.
A, SHIH C, LOPEZ DE URALDE Baminobenzimidazole-based al.: Design of potent and
kinase inhibitors with excellent p38alpha selective 2-in vivoMAP ef -20. cacy. DUMAS J, HATOUM-MOKDAD H, SIBLEY RNJ Med Chem 2005, 48: 2270-3.
et
acterization of a potent, orally active p38 ki-al.: Synthesis and pharmacological char-nase inhibitor. 21. 12: 1559-62.
Bioorg Med Chem Lett 2002, REVESZ Novel p38 inhibitors with potent oral ef ca-L, BLUM E, DI PADOVA FE et al.:
cy in several models of rheumatoid arthritis. 22. Bioorg Med Chem Lett WADA 2004, 14: 3595-9.KY, NAKAJIMA-YAMADA T, YAMADA
MAPK, ameliorates hyperalgesia and swell- et al.: R-130823, a novel inhibitor of p38 ing in arthritis models. Eur J Pharmacol 23. 2005, 506: 285-95.
FRANTZ activation state of p38 mitogen-activated pro-B, KLATT T, PANG M et al.: The
tein kinase determines the ef ciency of ATP competition for pyridinylimidazole inhibitor 24. binding. BRANGER J, Biochemistry al.togen-activated protein kinase inhibitor dur-: Anti-in ammatory VAN DEN BLINK B, WEIJER S1998; 37: 13846-53.effects of a p38 mi- et
ing human endotoxemia. J Immunol 25. 168: 4070-7.
2002, FIJEN Suppression JW, ZIJLSTRA of the JG, clinical DE BOER and Pcytokine et al.:
185
hresponse p38 mitogen-activated protein-kinase inhibi-to endotoxin by RWJ-67657, a tor, in healthy human volunteers. Clin Exp 26. Immunol BIRRELL MA, WONG S, M2001, 124: 16-20.
Second-generation CCLUSKIE K et al.:
the protein kinase in post-transcriptional modu-involvement of inhibitors p38 mitogen-activated demonstrate lation in human and rodent of in ammatory airways. mediator J Pharmacol production 27. Exp Ther DUAN W, CHAN JH, M2006, 316: 1318-27.
p38alpha CKAY K et al.: Inhaled
antisense mitogen-activated protein kinase in mice. Am oligonucleotide J Respir Crit attenuates Care Med asthma 2005, 28. 171: 571-8.
TRIFILIEFF A, KELLER TH, PRESS NJCGH2466, antagonist, p38 mitogen-activated protein ki-a combined adenosine receptor et al.:
nase and phosphodiesterase type 4 inhibitor with potent matory activities. in vitro and in vivo anti-in am-29. 1002-10.
Br J Pharmacol 2005, 144: UNDERWOOD et al.DC, OSBORN RR, KOTZER CJinhibitor, reduces in ammatory cytokine pro-: SB 239063, a potent p38 MAP kinase
duction, persistence. airways J Pharmacol eosinophil Exp in ltration, Ther 2000, and 30. 293: 281-8.
DODELLER F, SCHULZE-KOOPS Hmitogen-activated cascade in CD4 T protein cells. Arthritis kinase : The p38
signaling 31. 2006, 8: 205.
Res Ther BARSYTE-LOVEJOY ROCKS MAPK signaling AD: Speci city D, GALANIS to transcription determinants A, SHAR-factors. in 32. J Biol Chem GALE LIER EA, BINGLEY 2002, 277: 9896-903.
PJ, Intervention T: European EMMETT CL, COL-controlled Trial (ENDIT): Nicotinamide a randomised Diabetes onset of type 1 diabetes. trial of intervention Lancet before 2004, 363: the 33. 925-31.
PERETTO Synthesis I, RADAELLI S, PARINI C et al.:
biprofen of beta-amyloid(1)(-)(42) analogues and biological as selective activity of ur-secretion. inhibitors J 34. Chem LEE inhibitors: MR, 2005, 48: 5705-20.
Med DOMINGUEZ look at their interactions with p38alpha pro-clinical results C: MAP and an kinase intimate p38
tein. Curr Med Chem 2005, 12: 2979-94.
p38 inhibition and not MK2 inhibition enhances ...efficacy in in vitro and in vivo inflammatory ... Novel inhibitor of p38 MAP kinase as an anti...
(2013) In Vitro and In Vivo Experimental Models...Efficacy of Antineoplastic Drugs on Urinary Bladder...inhibition are the oldest and most commonly used ...
The potent anti-leukemia efficacy of Icaritin in murine model demonstrated ... Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a...
of 4T1 breast cancer in vitro and in vivo. ...In vivo growth-inhibition of Sarcoma 180 by ...Chemopreventive efficacy of curcumin and piperine ...
namely stimulation of osteoblastic cell proliferation and inhibition of ...In summary, the present study clearly demonstrates the in vivo efficacy of ...
Experimental models of elevated Pgc in vivo ...In vitro mechanical stimulation therefore represents ...of p38 MAP kinase and subsequent inhibition by ...
Target validation Seattle/Chicago: Structure ...(in vitro systems) Biochemical (kinase, protease,...Inhibition Slide 20 deCODE Capabilities: In Vivo ...
In vitro models (enzyme inhibition, receptor ...and in silico) Bottleneck: Target validation, “... www.kubinyi.de MAP Kinase Pathways Kinases www....
[1] Target: p38 MAPK in vitro: In SHR-SPs receiving a salt-fat diet...Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, ...
Efficacy of a Tyrosine... 暂无评价 9页 免费 ...in vitro screening for tyrosine kinase inhibitors ...Also, there is substantial in vivo inhibition of...
热门文档